As an example, sorafenib was shown to disrupt the mitochondrial membrane potential in RCC, leading to increased ROS and thus breaking resistance to TNF (Tumor necrosis factor) -related apoptosis inducing ligand (TRAIL)-induced apoptosis [127]. Here, TNF is linked to renal cell carcinoma.